Download PDF
Open Access
CC BY 4.0 · Endoscopy
DOI: 10.1055/a-2710-6551
Original article

Endoscopic eradication therapy with multifocal cryoballoon ablation for Barrett esophagus-related neoplasia: a prospective European multicenter study

Authors

  • Charlotte Frederiks 

    1   Gastroenterology and Hepatology, UMC Utrecht, Utrecht, Netherlands (Ringgold ID: RIN8124)
    2   Gastroenterology and Hepatology, St Antonius Hospital, Nieuwegein, Netherlands (Ringgold ID: RIN6028)

  • Anouk Overwater

    2   Gastroenterology and Hepatology, St Antonius Hospital, Nieuwegein, Netherlands (Ringgold ID: RIN6028)
    3   Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, Netherlands (Ringgold ID: RIN8124)

  • Torsten Beyna 

    4   Internal Medicine, Evangelisches Krankenhaus Dusseldorf, Düsseldorf, Germany (Ringgold ID: RIN39751)

  • Horst Neuhaus

    5   Gastroenterology, Evangelisches Krankenhaus Dusseldorf, Düsseldorf, Germany (Ringgold ID: RIN39751)

  • Raf Bisschops 

    6   Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium (Ringgold ID: RIN60182)

  • Roos E. Pouw

    7   Gastroenterology and Hepatology, Amsterdam UMC Locatie AMC, Amsterdam, Netherlands (Ringgold ID: RIN26066)
    1   Gastroenterology and Hepatology, UMC Utrecht, Utrecht, Netherlands (Ringgold ID: RIN8124)

  • Jacques JGHM Bergman

    7   Gastroenterology and Hepatology, Amsterdam UMC Locatie AMC, Amsterdam, Netherlands (Ringgold ID: RIN26066)

  • Maximilien Barret

    8   Gastroenterology and Digestive Oncology, Hopital Cochin, Paris, France (Ringgold ID: RIN26935)

  • Roberta Maselli

    9   Gastroenterology, IRCCS Istituto Clinico Humanitas, Rozzano, Italy (Ringgold ID: RIN9268)

  • Vinay Sehgal

    10   Gastroenterology, University College London Hospitals NHS Foundation Trust, London, United Kingdom of Great Britain and Northern Ireland (Ringgold ID: RIN8964)

  • Rehan Haidry

    11   DDSI, Cleveland Clinic London Ltd, London, United Kingdom of Great Britain and Northern Ireland (Ringgold ID: RIN591481)

  • Bas L.A.M. Weusten 

    2   Gastroenterology and Hepatology, St Antonius Hospital, Nieuwegein, Netherlands (Ringgold ID: RIN6028)
    12   Department of Gastroenterology & Hepatology, Utrecht University, Utrecht, Netherlands (Ringgold ID: RIN8125)

Supported by: Pentax Medical

Clinical Trial:

Registration number (trial ID): NL-OMON50590, Trial registry: Netherlands National Trial Register (http://www.trialregister.nl), Type of Study: Prospective, multicenter, single-arm, intervention study


Further Information
Also available at
 PDF Download

Background Focal cryoballoon ablation (FCBA) is a relatively new ablation modality for the treatment of Barrett esophagus (BE)-related neoplasia. This prospective, multicenter study aimed to evaluate the efficacy and safety of FCBA for the treatment of BE. Methods In eight European Barrett expert centers, patients with a C≤2M≤5 BE segment (according to Prague classification) with dysplasia or early cancer were eligible for inclusion. Before entry, any visible lesion if present had to be removed by endoscopic resection (ER). FCBA was performed by trained endoscopists at 3-month intervals until complete eradication of BE (max. 5 sessions). After at least two FCBA sessions, add-on treatment was allowed. Post-treatment, follow-up endoscopy was scheduled at 6 months and annually thereafter. Outcomes were complete eradication of endoscopically visible BE (CE-BE), intestinal metaplasia (CE-IM), and dysplasia (CE-D), durability of treatment response and adverse events. Results 107 patients (91 males; mean age 65) with a median BE of C0M2 were included. ER at entry was performed in 65% (69/107) followed by a median of 2 FCBA treatments. Add-on treatment was performed in 40% (43/107), mainly APC for small remaining islands (38%; 41/107). CE-BE and CE-D was achieved in 94% (101/107; 95% CI 90%-98%) and CE-IM in 91% (97/107; 95% CI 85%-95%), per intention-to-treat analysis. Per-protocol analysis, CE-BE and CE-D was achieved in 100% (101/101; 95% CI 100%-100%), and CE-IM in 96% (97/101; 95% CI 92%-99%). After a median follow-up of 18 months, 96% (97/101; 95% CI 92%-99%) remained free of endoscopically visible BE. Esophageal stricture was the most common adverse event in 13% (13/101; 95% CI 6%-20%). Conclusion In expert hands, endoscopic eradication therapy with FCBA is highly effective in selected patients with BE of limited length, although the potential risk for stricture formation warrants further research



Publication History

Received: 30 January 2025

Accepted after revision: 25 September 2025

Accepted Manuscript online:
26 September 2025

© . The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/).

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany